[go: up one dir, main page]

MX2009003039A - Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer. - Google Patents

Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.

Info

Publication number
MX2009003039A
MX2009003039A MX2009003039A MX2009003039A MX2009003039A MX 2009003039 A MX2009003039 A MX 2009003039A MX 2009003039 A MX2009003039 A MX 2009003039A MX 2009003039 A MX2009003039 A MX 2009003039A MX 2009003039 A MX2009003039 A MX 2009003039A
Authority
MX
Mexico
Prior art keywords
antibody
cancer
treatment
inhibiting
protein
Prior art date
Application number
MX2009003039A
Other languages
English (en)
Inventor
Jean-Francois Haeuw
Liliane Goetsch
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37866318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009003039(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2009003039A publication Critical patent/MX2009003039A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención tiene por objeto la utilización de al menos un anticuerpo, o uno de sus fragmentos funcionales, capaz de unirse a la proteína CD151 e inhibir así el crecimiento tumoral para la preparación de un medicamento destinado al tratamiento del cáncer. La invención pretende igualmente una composición para el tratamiento del cáncer, que comprende como principio activo al menos un anticuerpo anti-CD151, o uno de sus fragmentos funcionales, capaz de unirse a la proteína CD151 y/o de inhibir el desarrollo de tumores primarios y/o de inhibir su actividad promotora de metástasis, pudiendo consistir dichos anticuerpos en los anticuerpos TS151 y/o TS151r.
MX2009003039A 2006-10-18 2007-10-15 Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer. MX2009003039A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0609135A FR2907341B1 (fr) 2006-10-18 2006-10-18 Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
PCT/FR2007/001688 WO2008049990A2 (fr) 2006-10-18 2007-10-15 Utilisation d'un anticorps anti-cd151 pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MX2009003039A true MX2009003039A (es) 2009-04-02

Family

ID=37866318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003039A MX2009003039A (es) 2006-10-18 2007-10-15 Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.

Country Status (27)

Country Link
US (2) US8178096B2 (es)
EP (1) EP2079482B1 (es)
JP (2) JP5757646B2 (es)
KR (1) KR101521863B1 (es)
CN (1) CN101528256B (es)
AT (1) ATE499387T1 (es)
AU (1) AU2007310763B2 (es)
BR (1) BRPI0717455A2 (es)
CA (1) CA2665912C (es)
DE (1) DE602007012743D1 (es)
DK (1) DK2079482T3 (es)
ES (1) ES2361696T3 (es)
FR (1) FR2907341B1 (es)
HR (1) HRP20110374T1 (es)
IL (1) IL198043A (es)
MA (1) MA30777B1 (es)
MX (1) MX2009003039A (es)
NO (1) NO20091919L (es)
NZ (1) NZ575781A (es)
PL (1) PL2079482T3 (es)
PT (1) PT2079482E (es)
RS (1) RS51729B (es)
RU (1) RU2464041C2 (es)
SI (1) SI2079482T1 (es)
TN (1) TN2009000144A1 (es)
UA (1) UA99601C2 (es)
WO (1) WO2008049990A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
FR2929946B1 (fr) * 2008-04-11 2010-05-28 Pf Medicament Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer
EP2308897A1 (en) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
CN102605057A (zh) * 2012-02-28 2012-07-25 芮屈生物技术（上海）有限公司 癌症病变前期CD151的mRNA水平原位杂交检测试剂盒及检测方法和应用
US9982057B2 (en) 2014-11-17 2018-05-29 Pelican Therapeutics, Inc. Human TNFRSF25 antibody
WO2017214547A1 (en) 2016-06-09 2017-12-14 Pelican Therapeutics, Inc. Anti-tnfrsf25 antibodies
US11608384B2 (en) * 2017-04-05 2023-03-21 Xdcexplorer (Shanghai) Co., Ltd. Humanized anti-TPBG antibody, preparation method therefor, conjugate thereof, and applications

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
WO1999066027A1 (en) * 1998-06-15 1999-12-23 The Research Foundation Of State University Of New York Monoclonal antibodies that recognize antigens associated with tumor metastasis
JP2003189851A (ja) * 2001-12-28 2003-07-08 Japan Science & Technology Corp 抗ヒトｃｄ１５１モノクローナル抗体産生ハイブリドーマ
JP2003321494A (ja) * 2002-02-26 2003-11-11 Daiichi Fine Chemical Co Ltd プロｍｍｐ−７の活性化調節方法
WO2007150020A1 (en) * 2006-06-23 2007-12-27 Simon Paul M Targeted immune conjugates
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
FR2929946B1 (fr) * 2008-04-11 2010-05-28 Pf Medicament Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer

Also Published As

Publication number Publication date
WO2008049990A2 (fr) 2008-05-02
CN101528256B (zh) 2013-10-02
WO2008049990A3 (fr) 2008-09-12
BRPI0717455A2 (pt) 2013-12-24
IL198043A0 (en) 2011-08-01
US8178096B2 (en) 2012-05-15
UA99601C2 (ru) 2012-09-10
RU2009118440A (ru) 2010-11-27
TN2009000144A1 (fr) 2010-10-18
HRP20110374T1 (hr) 2011-06-30
NZ575781A (en) 2012-06-29
JP5757646B2 (ja) 2015-07-29
US20120219569A1 (en) 2012-08-30
KR101521863B1 (ko) 2015-05-20
EP2079482B1 (fr) 2011-02-23
PT2079482E (pt) 2011-05-25
AU2007310763A1 (en) 2008-05-02
EP2079482A2 (fr) 2009-07-22
FR2907341B1 (fr) 2012-08-17
ES2361696T3 (es) 2011-06-21
JP2010506888A (ja) 2010-03-04
KR20090067219A (ko) 2009-06-24
FR2907341A1 (fr) 2008-04-25
US20090324600A1 (en) 2009-12-31
MA30777B1 (fr) 2009-10-01
CA2665912A1 (fr) 2008-05-02
SI2079482T1 (sl) 2011-07-29
PL2079482T3 (pl) 2011-07-29
CA2665912C (fr) 2014-12-09
RS51729B (sr) 2011-10-31
HK1132904A1 (en) 2010-03-12
AU2007310763B2 (en) 2011-02-17
RU2464041C2 (ru) 2012-10-20
DE602007012743D1 (de) 2011-04-07
ATE499387T1 (de) 2011-03-15
IL198043A (en) 2015-03-31
JP2013253084A (ja) 2013-12-19
DK2079482T3 (da) 2011-06-14
CN101528256A (zh) 2009-09-09
JP5723420B2 (ja) 2015-05-27
NO20091919L (no) 2009-05-18

Similar Documents

Publication Publication Date Title
MX2009003039A (es) Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.
MX349198B (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
WO2010019702A3 (en) Ddr1-binding agents and methods of use thereof
WO2008142303A3 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
WO2014012007A3 (en) Rspo3 binding agents and uses thereof
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
WO2010005566A3 (en) Notch-binding agents and antagonists and methods of use thereof
IL214325A (en) Antibody against cmet, a drug that includes and uses it
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
WO2008091641A3 (en) Compositions and methods for diagnosing and treating cancer
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
EP2175879A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
BRPI0514721A (pt) uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
UA94213C2 (ru) Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания
GB0507598D0 (en) Composition
WO2007007152A3 (en) Anti-madcam antibodies to treat metastatic cancers and chloroma
ATE492564T1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
FR2929519B1 (fr) Utilisation d'un anticorps anti-cd151 pour le traitement precoce des cancers.
UA101671C2 (ru) Notch-связующие агенты и антагонисты и способы их применения

Legal Events

Date Code Title Description
FG Grant or registration